

EVENTO RESIDENZIALE ECM (CME Information):

n. **740 – 471759** Edizione n° 1
Titolo: **MM BRIDGE - BRIDGING SCIENCE AND CARE IN MULTIPLE MYELOMA CURRENT PRACTICE AND EMERGING ADVANCES**

All'evento sono stati assegnati **9 crediti ECM**

Destinatari dell'iniziativa:
MEDICO CHIRURGO con specializzazione in: EMATOLOGIA; GENETICA MEDICA; MEDICINA INTERNA; ONCOLOGIA; ANATOMIA PATOLOGICA; BIOCHIMICA CLINICA; LABORATORIO DI GENETICA MEDICA; PATOLOGIA CLINICA (LABORATORIO DI ANALISI CHIMICO-CLINICHE E MICROBIOLOGIA);

Obiettivo formativo: **3 – Documentazione clinica. Percorsi clinico-assistenziali diagnostici e riabilitativi, profili di assistenza - profili di cura.**

Sede del corso:
Hotel Duo Milan
VIA GEROLAMO CARDANO, 1 MILANO

MATTIOLIHEALTH 

SEGRETERIA ORGANIZZATIVA E PROVIDER ECM (ID 740)
MATTIOLI 1885
SRL / STRADA DELLA LODESANA, 649/SX
43036 FIDENZA (PR) TEL. 0524 530383 - FAX 0524 82537
MAIL: ECM@MATTIOLI1885.COM | WWW.MATTIOLI1885.COM

WITH THE PATRONAGE OF:

   

   **UNIVERSITÀ DEGLI STUDI DI MILANO**

SIE — Società Italiana Ematologia

WITH AN UNRESTRICTED GRANT OF:

  

  

 

MMBRIDGE

Bridging Science and Care in Multiple Myeloma
Current Practice and Emerging Advances

EVENTO RESIDENZIALE ECM

12-13 MARZO 2026 | MILANO
Hotel Duo Milan
Via Gerolamo Cardano, 1 Milano

SCIENTIFIC DIRECTORS

NICCOLÒ BOLLI, **MILANO** | MATTEO CLAUDIO DA VIÀ, **MILANO**

Scientific Rationale

The treatment of Multiple Myeloma has undergone significant changes in recent years thanks to advancements in understanding the disease and the increasing availability of new therapeutic agents.

A better understanding of the biology of Multiple Myeloma has made it possible to more accurately identify patients with aggressive disease who require treatment, as well as to stratify the likelihood of response to therapy and long-term survival. New diagnostic approaches, including flow cytometry, radiological, and molecular techniques, now allow the identification of high-risk factors and the measurement of minimal residual disease (MRD) with a sensitivity that was unimaginable just a few years ago.

Advances in therapy have provided clinicians with a vast arsenal of treatment options: the field has shifted from standardized therapy for all patients based on transplant eligibility to the availability of multiple drug combinations for each line of therapy, requiring increasingly personalized choices. MRD is a new primary endpoint in clinical trials, and in daily clinical practice it will enable targeted personalized therapeutic decisions.

This conference will bring together national and international experts to provide a comprehensive and cross-disciplinary overview of the current state of knowledge on Multiple Myeloma, from its biological foundations to the latest diagnostic and therapeutic innovations. Only through a deep understanding by healthcare and research professionals of the changes in the field of Multiple Myeloma will it be possible for patients to fully benefit from the progress achieved so far and from those yet to come.

MATTIOLIHEALTH 

GIOVEDÌ 12 MARZO 2026

- 13:00 Lunch and Registration
- 14:00 Welcome and opening remarks
Niccolò Bolli, Matteo Claudio Da Vià, Francesco Passamonti

SESSION 1 - THE TUMOR MICROENVIRONMENT AND PRE-CLINICAL DEVELOPMENT OF MYELOMA

Chairs: Alessandra Romano, Antonio Solimando

- 14:30 Genomic determinants of aggressiveness of precursor conditions
Niccolò Bolli
- 14:42 The pathogenic role of immune tumor microenvironment in the development of Multiple Myeloma
Tom Cupedo
- 14:54 Discussion

SESSION 2 - HOW AND WHEN WE TREAT MYELOMA?

Chairs: Michele Cea, Carmine Liberatore

- 15:10 Curative vs delaying approach to the treatment of smoldering Myeloma
Maria-Victoria Mateos
- 15:22 To treat myeloma, we exploit the vulnerabilities of normal plasma cells
Simone Cenci
- 15:34 To treat myeloma, we target the aberrant pathways of a clonal plasma cell
Jan Kronke
- 15:46 What is new in treatment algorithms of TE patients?
Elena Zamagni
- 15:58 Discussion
- 16:17 Coffee Break

SESSION 3 - WHAT ARE THE CURRENT PROGNOSTIC FEATURES IN MULTIPLE MYELOMA?

Chairs: Daniele Derudas, Roberto Ria

- 16:37 Circulating plasma cells: how should we measure them and how many are too much?
Luca Bertamini
- 16:49 Genetic prognostic and predictive factors in NDMM
Mattia D'Agostino
- 17:01 Will transcriptomics ever find its place in Myeloma prognostication?
Martin Kaiser
- 17:13 Discussion

SESSION 4 - FIRST-LINE TREATMENT OF MULTIPLE MYELOMA AND BIOLOGICAL DETERMINANTS OF RESPONSE

Chairs: Vittorio Montefusco, Loredana Pettine

- 17:37 Immunogenic cell death: predictive markers and modifiers
Annamaria Gullà
- 17:49 Intrinsic and extrinsic mechanisms of resistance to daratumumab and IMiDs
Eileen Boyle
- 18:01 Quadruplets in NTEM: for the many or for the few?
Salomon Manier
- 18:13 New perspectives in first line treatment from European Myeloma Network trials
Mario Boccadoro
- 18:25 Discussion
- 18:40 END OF DAY 1

VENERDÌ 13 MARZO 2026

SESSION 5 - POST-INDUCTION RESPONSE ASSESSMENT AND NOVEL STRATEGIES OF CLINICAL MANAGEMENT

Chairs: Ciro Botta, Renato Zambello

- 09:00 NGS for risk assessment at diagnosis and MRD measurement
Carolina Terragna
- 09:12 Bone marrow and Peripheral Blood Residual Disease by NGF and other methods
Bruno Paiva
- 09:24 MRI and PET-CT to evaluate treatment response.
Angelo Belotti
- 09:36 Current and future maintenance strategies: for who, for how long?
Francesca Gay
- 09:48 Discussion

SESSION 6 - HOW DO WE APPROACH RELAPSED MYELOMA WITHOUT T-CELL REDIRECTING THERAPIES TODAY?

Chairs: Monica Galli, Maria Teresa Petrucci

- 10:15 Anti-CD38 treatments in relapsed-refractory myeloma
Enrique Ocio
- 10:27 Anti-BCMA ADC combinations at first relapse
Sara Bringhen
- 10:39 Novel small molecules in the treatment of myeloma
Gabriele Buda
- 10:51 Indications and efficacy of Celmods
Fredrik Schjesvold
- 11:03 Discussion
- 11:25 Coffee Break

SESSION 7 - T-CELL REDIRECTING THERAPIES FOR REFRACTORY MYELOMA

Chairs: Paolo Corradini, Francesco Passamonti

- 11:45 Latest updates on CAR-T treatment
Hermann Einsele
- 11:57 Bispecific antibodies in relapsed-refractory myeloma
Cyrille Touzeau
- 12:09 Resistance to anti-BCMA and anti-GPRC5D
Niels Weinhold
- 12:21 How to manipulate/rest the microenvironment for improving T-cell redirection
Leo Rasche
- 12:33 Discussion
- 13:00 Lunch

SESSION 8 - PATIENT SELECTION AND STRATEGIES TO MAXIMIZE EFFICACY OF T-CELL BASED IMMUNOTHERAPIES

Chairs: Massimo Gentile, Francesca Patriarca

- 14:30 Why treat a patient with CAR-T? A case report
Francesca Farina
- 14:40 Why treat a patient with a T-cell engager? A case report
Silvia Mangiacavalli
- 14:50 Immunological bases for efficacy of T-cell redirecting therapies, or lack thereof
Mirco Friedrich
- 15:05 The Future of Immunotherapy in MM
Marc Raab
- 15:20 Discussion

SESSION 9 - FUTURE APPROACHES IN THE TREATMENT OF MYELOMA

Chairs: Massimo Martino, Pellegrino Musto

- 15:45 Trispecific antibodies in RRMM
Matteo Claudio Da Vià
- 15:57 Ad-hoc trials for high-risk patients
Maximilian Al-Bazaz
- 16:09 What will it take to implement outpatient management of CAR-T/ TCE patients?
Stefania Bramanti
- 16:23 Future CAR-T approaches in myeloma
Michael Hudecek
- 16:45 Discussion
- 17:10 CLOSING REMARKS AND ADJOURN
Niccolò Bolli, Matteo Claudio Da Vià

Faculty

- Maximilian Al-Bazaz (Hamburg, DE)

Angelo Belotti (Brescia)

Luca Bertamini (Rotterdam, NL)

Mario Boccadoro (Torino)

Niccolò Bolli (Milano)

Cirino Botta (Palermo)

Eileen Boyle (London, UK)

Stefania Bramanti (Milano)

Sara Bringhen (Cuneo)

Gabriele Buda (Pisa)

Michele Cea (Genova)

Simone Cenci (Milano)

Paolo Corradini (Milano)

Tom Cupedo (Rotterdam, NL)

Matteo Claudio Da Vià (Milano)

Mattia D'Agostino (Torino)

Daniele Derudas (Cagliari)

Hermann Einsele (Würzburg, DE)

Francesca Farina (Milano)

Mirko Friedrich (Heidelberg, DE)

Monica Galli (Bergamo)

Francesca Gay (Torino)

Massimo Gentile (Cosenza)

Annamaria Gullà (Candiolo)

Michael Hudecek (Würzburg, DE)

Martin Kaiser (London, UK)
- Jan Krönke (Greifswald, DE)

Carmine Liberatore (Pescara)

Silvia Mangiacavalli (Pavia)

Salomon Manier (Lille, FR)

Massimo Martino (Reggio Calabria)

Maria-Victoria Mateos (Salamanca, ES)

Vittorio Montefusco (Milano)

Pellegrino Musto (Bari)

Enrique Ocio (Santander, ES)

Bruno Paiva (Pamplona, PT)

Francesco Passamonti (Milano)

Francesca Patriarca (Udine)

Maria Teresa Petrucci (Roma)

Loredana Pettine (Milano)

Marc Raab (Heidelberg, DE)

Leo Rasche (Würzburg, DE)

Roberto Ria (Bari)

Alessandra Romano (Catania)

Fredrik Schjesvold (Oslo, NO)

Antonio Giovanni Solimando (Bari)

Carolina Terragna (Bologna)

Cyrille Touzeau (Nantes, FR)

Niels Weinhold (Heidelberg, DE)

Elena Zamagni (Bologna)

Renato Zambello (Padova)